Clinical trial
A Phase I/II Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)
NCT05048901 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/II Study Using Cabozantinib and Lanreotide as Treatment for Advanced Gastroenteropancreatic Neuroendocrine Tumors That Failed Molecular Targeted Therapies or Chemotherapy (SCALET)
- Lead sponsor
- National Health Research Institutes, Taiwan
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- September 17, 2021
- Completion date
- December 31, 2027
- Enrollment
- 49 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
neuroendocrine tumors,gastroenteropancreatic